Discovery and Functional Annotation of SIX6 Variants in Primary Open-Angle Glaucoma

Citation

Published Version
doi:10.1371/journal.pgen.1004372

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406781

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Discovery and Functional Annotation of SIX6 Variants in Primary Open-Angle Glaucoma

Megan Ulmer Carnes1,9, Yangfan P. Liu3*†, R. Rand Allingham3, Benjamin T. Whigham3, Shane Havens3, Melanie E. Garrett1, Chunyan Qiao4,5, NEIGHBORHOOD Consortium Investigators‡, Nicholas Katsanis2, Janey L. Wiggs4, Louis R. Pasquale4,6, Allison Ashley-Koch1,7, Edwin C. Oh2,8, Michael A. Hauser1,3,7,*

1 The Center for Human Genetics, Duke University, Durham, North Carolina, United States of America, 2 The Center for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America, 3 Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, United States of America, 4 Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States of America, 5 Beijing Tongren Hospital, Beijing Tongren Eye Center, Beijing Ophthalmology & Visual Sciences Key Laboratory, Capital Medical University, Beijing, China, 6 Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 7 Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, 8 Department of Neurology, Duke University Medical Center, Durham, North Carolina, United States of America

Abstract
Glucoma is a leading cause of blindness worldwide. Primary open-angle glaucoma (POAG) is the most common subtype and is a complex trait with multigenic inheritance. Genome-wide association studies have previously identified a significant association between POAG and the SIX6 locus (rs10483727, odds ratio (OR) = 1.32, p = 3.87 x 10^-11). SIX6 plays a role in ocular development and has been associated with the morphology of the optic nerve. We sequenced the SIX6 coding and regulatory regions in 262 POAG cases and 256 controls and identified six nonsynonymous coding variants, including five rare and one common variant, Asn141His (rs33912345), which was associated significantly with POAG (OR = 1.27, p = 4.2 x 10^-10) in the NEIGHBOR/GLAUGEN datasets. These variants were tested in an in vivo Danio rerio (zebrafish) complementation assay to evaluate ocular metrics such as eye size and optic nerve structure. Five variants, found primarily in POAG cases, were hypomorphic or null, while the sixth variant, found only in controls, was benign. One variant in the SIX6 enhancer increased expression of SIX6 and disrupted its regulation. Finally, to our knowledge for the first time, we have identified a clinical feature in POAG patients that appears to be dependent upon SIX6 genotype: patients who are homozygous for the SIX6 risk allele (His141) have a statistically thinner retinal nerve fiber layer than patients homozygous for the SIX6 non-risk allele (Asn141). Our results, in combination with previous SIX6 work, lead us to hypothesize that SIX6 risk variants disrupt the development of the neural retina, leading to a reduced number of retinal ganglion cells, thereby increasing the risk of glaucoma-associated vision loss.

Introduction
Primary open-angle glaucoma (POAG) is the most common type of glaucoma, a group of diseases that affect approximately 60 million people worldwide and is a leading cause of blindness [1]. Glaucoma is characterized by the progressive death of retinal ganglion cells, leading to optic nerve atrophy and loss of vision. POAG is a complex inherited disorder for which an increasing number of genetic associations have been described, each contributing modestly to disease burden [2,3].

A recent POAG genome-wide association study found a significant genetic association (rs10483727, odds ratio (OR) = 1.32, p = 3.87 x 10^-11) at the SIX1/SIX6 locus [4]. Variants in the SIX1/SIX6 locus were first associated with quantitative optic nerve parameters in controls, including vertical cup-disc ratio (VCDR), which is used clinically to diagnose and monitor POAG progression [5,6]. Several studies have independently confirmed the association of the SIX1/SIX6 locus with both VCDR and POAG [7–9].

The human SIX family gene consists of six members (SIX1–SIX6), all of which contain two shared protein domains; a DNA binding homeobox domain and a SIX domain, which binds downstream effector molecules [10,11]. Members of this conserved gene family were originally identified through homology to the Drosophila melanogaster (Drosophila) sine cura (so) gene, which is
Author Summary

Primary open angle glaucoma is a blinding disease for which there is currently no cure, only treatments that may slow its progression. To help understand the mechanisms of this disease and to design more effective treatments, we identified previously a locus, SIX6, that increases the risk of glaucoma. This gene is involved in early eye development and helps to form the retina. In this paper, we test specific sequence variants in SIX6 that are found in glaucoma patients. We show that these variants have a reduced function that interferes with their ability to direct proper formation of the retina. One variant in particular is common, and may be the main reason that this gene is important in the glaucoma disease process. Patients who have two copies of this sequence variant show a change in the structure of their eye consistent with fewer neurons that carry the visual signal to the brain. These neurons typically die as people age, and people who begin life with fewer visual neurons may have an increased risk of glaucoma. Additional research in this topic may lead to new treatments that preserve sight.

Results

Identification of SIX6 risk alleles in POAG cases

Sequencing of the SIX1 and SIX6 genes in Caucasian POAG cases and controls (262 cases, 256 controls) revealed 23 SNPs (Supplemental Table S1). Nine SNPs were identified in SIX1, but no nonsynonymous SNPs were present in the POAG cases. Sequencing of SIX6 yielded 14 variants including five rare nonsynonymous SNPs in POAG cases and controls, one common nonsynonymous SNP located in the homeobox of SIX6 (rs33912345, Asn141His), and five sequence variants within the SIX6 enhancer. All of these variants are conserved evolutionarily as shown by their positive Genomic Evolution Rate Profiling (GERP) scores (Table 1) [17].

Genotyping of rs33912345 in the Duke POAG case-control dataset (482 cases, 435 controls) resulted in a significant association (OR = 1.40, p = 0.0005, POAG case minor allele frequency (MAF) = 0.47, POAG control MAF = 0.39) with POAG. This SNP is in high linkage disequilibrium ($r^2 = 0.95$) with the intergenic SNP identified originally in POAG and VCDR genome-wide association studies (rs10483727) [4–6,13]. As expected, meta-analysis of the imputed genotype data from the NEIGHBOR and GLAUGEN studies confirmed a significant association between POAG status and rs33912345 (OR = 1.27, p = 4.2 × 10$^{-10}$) and other linked SNPs in the region (Supplemental Table S2). Further examination of this locus showed that the association signal includes both upstream and downstream regions of the SIX6 transcript, while remaining entirely downstream of SIX1 (Supplemental Figure S1).

We next performed optical coherence tomography (OCT) to study the retinal characteristics of POAG cases possessing the SIX6 risk and non-risk variants (Table 2). OCT images were only available for POAG cases with the common SNP, rs33912345; no data were available for individuals with the rare SIX6 variants. We assessed retinal nerve fiber layer (RNFL) thickness in thirty POAG cases homozygous for the rs33912345 risk allele (C) or the non-risk allele (A) first by comparing age at disease diagnosis and age at OCT across the two genotypes, because age is known to influence retinal thickness and is thus a potential confounder. We observed no significant difference in age (p = 0.11, p = 0.14, respectively). Next, RNFL thickness was evaluated. The overall thickness (global RNFL) was reduced significantly in cases homozygous for the risk allele compared to cases with the non-risk allele (p = 0.033; mean (SD); C = 58.3 (8.2) µm, A = 67.9 (12.4) µm; Table 2), consistent with the hypothesis that SIX6 may increase POAG susceptibility via changes in the neural retina. To determine which quadrants might be driving this observation, we performed an exploratory, post-hoc comparison of RNFL thickness in the temporal, nasal, inferior, and superior regions. We found that RNFL thickness was reduced significantly in the inferior (p = 0.033) and superior (p = 0.04) quadrants, the two regions affecting directly VCDR measurements.

In vivo functional interrogation of SIX6 missense variants

Given 1) the observed association signal pattern; 2) the lack of coding changes identified in SIX1; 3) the presence of rare missense variants and a common, associated missense SNP in SIX6; 4) retinal nerve fiber layer thickness changes observed in POAG cases homozygous for the SIX6 risk allele; and 5) the localized expression of SIX6 in ocular tissues, we concluded SIX6 is a likely candidate gene in this region. We therefore evaluated the functional relevance of SIX6 and the potential burden of common and rare alleles in this locus in POAG using an in vivo zebrafish complementation assay. First, we performed a reciprocal BLAST analysis; we identified two orthologs of SIX6 in the zebrafish genome, Six6a and Six6b, both with 91% homology at the protein level (Supplemental Figure S2). Previous overexpression and loss of function studies of Six6 in Mus musculus (mouse) and Xenopus laevis (Xenopus) models reveal a role in regulating the proliferative state of retinal progenitor cells and the size of the eye [18,19]; therefore, as a first test of whether the identified SIX6 variants are pathogenic and
<table>
<thead>
<tr>
<th>Gene</th>
<th>Coordinates</th>
<th>SNP ID</th>
<th>MAF POAG Cases</th>
<th>MAF POAG Controls</th>
<th>Base Change</th>
<th>AA Change</th>
<th>GERP</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIX6</td>
<td>Chr14:60974363</td>
<td>----</td>
<td>0.002</td>
<td>0</td>
<td>G</td>
<td>Enhancer</td>
<td>3.77</td>
</tr>
<tr>
<td></td>
<td>Chr14:60974373</td>
<td>rs8004739</td>
<td>0.008</td>
<td>0</td>
<td>C</td>
<td>Enhancer</td>
<td>2.77</td>
</tr>
<tr>
<td></td>
<td>Chr14:60974378</td>
<td>----</td>
<td>0</td>
<td>0.002</td>
<td>C</td>
<td>Enhancer</td>
<td>2.77</td>
</tr>
<tr>
<td></td>
<td>Chr14:60974400</td>
<td>----</td>
<td>0.002</td>
<td>0.002</td>
<td>C</td>
<td>Enhancer</td>
<td>5.58</td>
</tr>
<tr>
<td></td>
<td>Chr14:60974449</td>
<td>----</td>
<td>0.002</td>
<td>0</td>
<td>A</td>
<td>Enhancer</td>
<td>3.48</td>
</tr>
<tr>
<td></td>
<td>Chr14:60976393</td>
<td>rs78954112</td>
<td>0</td>
<td>0.002</td>
<td>G</td>
<td>Glu93Gln</td>
<td>5.52</td>
</tr>
<tr>
<td></td>
<td>Chr14:60976501</td>
<td>rs146737847</td>
<td>0.008</td>
<td>0.002</td>
<td>G</td>
<td>Glu129Lys</td>
<td>5.38</td>
</tr>
<tr>
<td></td>
<td>Chr14:60976537</td>
<td>rs33912345</td>
<td>0.47</td>
<td>0.37</td>
<td>A</td>
<td>Asn141His</td>
<td>5.38</td>
</tr>
<tr>
<td></td>
<td>Chr14:60977843</td>
<td>rs45549246</td>
<td>0.002</td>
<td>0.002</td>
<td>T</td>
<td>Leu205Arg</td>
<td>4.14</td>
</tr>
<tr>
<td></td>
<td>Chr14:60977864</td>
<td>rs202029915</td>
<td>0.002</td>
<td>0</td>
<td>C</td>
<td>Thr212Met</td>
<td>2.36</td>
</tr>
<tr>
<td></td>
<td>Chr14:60977954</td>
<td>rs139302405</td>
<td>0.002</td>
<td>0</td>
<td>G</td>
<td>Ser242Ile</td>
<td>5.19</td>
</tr>
</tbody>
</table>

Coordinates are based on the Hg19 reference; MAF = minor allele frequency; AA = amino acid; GERP = Genomic Evolutionary Rate Profiling.

Given the reduction of the RNFL in cases homozygous for the risk allele, we next asked whether six6 and the identified SIX6 variants impacted the optic nerve, an anatomical site directly relevant to human POAG, in zebrafish. Using whole mount imaging of acetylated-tubulin expression in 2-dpf embryos injected with a control and six6 morpho, we evaluated volumetric regions of interest (ROI) along the optic nerve (Supplemental Figure S3). Masked scoring of embryos revealed an approximately 5 fold reduction (p<0.001) in the volume of the optic nerve upon deletion of six6 (Figure 3 A-B). This was specific for the optic nerve as the volume of other axonal tracts in the brain were unaffected by six6 depletion (Figure 3A). Specificity of the
volumetric measurements was demonstrated upon full rescue of the six6a morphant phenotype by co-injection of the non-risk allele (p < 0.001) or a variant that scored as a benign allele in the eye size assay (Glu93Gln; p < 0.001; Figure 3B). Both Leu205Arg and Asn141His variants performed as hypomorphic alleles (p < 0.01), revealing concordance of our optic nerve assay with the OCT imaging findings in patients.

**In vitro functional interrogation of SIX6 enhancer variants**

We hypothesized that POAG risk may be mediated not only by deficits in SIX6 protein function, but also by the level of SIX6 gene expression. To test this, we sequenced the SIX6 retinal specific enhancer element in 262 POAG cases and 256 POAG controls; we identified five variants (Chr14:60974363_C, Chr14:60974373_T, Chr14:60974378_T, Chr14:60974400_A, Chr14:60974449_G) (Table 1), and tested their effect on expression using an **in vitro** luciferase assay. We found that one of these variants (Chr14:60974449_G) resulted in a significant increase in expression compared to the reference enhancer (Figure 4). Activation of the SIX6 enhancer requires two cofactors, NeuroD and E47 (Supplemental Figure S4) [12]. Overexpression was observed with the Chr14:60974449_G variant even in the absence of these cofactors (Supplemental Figure S5), suggesting variants within the enhancer region may result in dysregulated protein expression.

**Discussion**

The SIX1/SIX6 locus has been shown to be associated significantly with POAG in several independent studies; however, the causal variant(s) driving this association have remained unknown [4,6–9,13], as has the direction of effect of these common alleles on protein function. We have demonstrated through several lines of evidence—the tissue specificity of the SIX gene family described in the literature; the identification of SIX6 missense variants in our POAG dataset; and the results of the in vivo and in vitro assays—that SIX6 is the most likely POAG susceptibility gene in this region. We identified both common and rare coding variants that alter the function of the SIX6 protein. We also identified a novel variant within the SIX6 enhancer that appears to disrupt the regulation of SIX6 expression, suggesting both regulatory and coding variants may influence POAG susceptibility at this locus. Finally, we identified hitherto unknown clinical features in POAG patients that may be dependent upon SIX6 genotype: patients homozygous for the SIX6 risk allele have a significantly thinner retinal nerve fiber layer than patients homozygous for the SIX6 non-risk allele.

The common variant, rs33912345 (Asn141His), which we showed has significantly reduced function in an in vivo model, was associated with POAG in our dataset and is in strong linkage disequilibrium with the originally identified GWAS SNP, rs10483727 [4]. This conserved amino acid is located within the alpha helix structure of the DNA homeobox domain of SIX6. Interestingly, the ancestral allele (C, His) is associated with POAG risk. The allele frequency of this variant differs markedly among populations (C allele frequency: YRI (0.99), ARF (0.96), ASN (0.76), and CEU (0.42); from 1000 Genomes release 14) [20]. This locus is associated significantly with an increase in

### Table 2. OCT measurements from POAG cases homozygous for rs33912345.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Allele</th>
<th>N</th>
<th>Mean (SD)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at POAG diagnosis (years)</td>
<td>A</td>
<td>18</td>
<td>63.9 (9.1)</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>69.7 (10.2)</td>
<td>0.00</td>
</tr>
<tr>
<td>Age at OCT measurement (years)</td>
<td>A</td>
<td>18</td>
<td>71.2 (9.7)</td>
<td>0.13</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>76.9 (10.3)</td>
<td>0.03</td>
</tr>
<tr>
<td>Nerve fiber thickness (μm): Global</td>
<td>A</td>
<td>18</td>
<td>67.9 (12.4)</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>58.3 (8.2)</td>
<td>0.85</td>
</tr>
<tr>
<td>Temporal</td>
<td>A</td>
<td>18</td>
<td>57.2 (15.2)</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>56.2 (12.8)</td>
<td>0.06</td>
</tr>
<tr>
<td>Nasal</td>
<td>A</td>
<td>18</td>
<td>57.4 (13.4)</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>47.9 (12.8)</td>
<td>0.03</td>
</tr>
<tr>
<td>Inferior</td>
<td>A</td>
<td>18</td>
<td>79.6 (18.7)</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>65.2 (12.6)</td>
<td>0.04</td>
</tr>
<tr>
<td>Superior</td>
<td>A</td>
<td>18</td>
<td>77.0 (22.2)</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>12</td>
<td>63.9 (10.8)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

SD = standard deviation; OCT = optical coherence tomography.

doi:10.1371/journal.pgen.1004372.t002

---

**Figure 1. Morpholino knockdown of six6a.** Zebrafish were microinjected with a six6a translation blocking morpholino. Lateral images, taken 3 days post fertilization (3 dpf), of a wild-type zebrafish (left) and a morpholino injected zebrafish (right) are shown, highlighting the small eye phenotype (dashed circle).

doi:10.1371/journal.pgen.1004372.g001
vertical cup-disc ratio (VCDR) in population controls, indicating that it may be involved in the development of the optic nerve. VCDR is also a clinical measure used to track disease progression in POAG patients [5,6,9,13,21]. We note that African populations have larger VCDR and an increase in overall POAG prevalence [22–24] compared to CEU populations; in a recent

Table 3. Results from the in vivo zebrafish six6a morpholino complementation assay.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>Mean (SD), μm²</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uninjected Control</td>
<td>146</td>
<td>53,140 (4,536)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Translation Blocker</td>
<td>153</td>
<td>34,042 (5,763)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Human SIX6 Non-risk allele</td>
<td>177</td>
<td>49,040 (11,652)</td>
<td>Ref</td>
</tr>
<tr>
<td>Glu93Gln Variant allele</td>
<td>92</td>
<td>50,010 (5,893)</td>
<td>0.37</td>
</tr>
<tr>
<td>Glu129Lys Variant allele</td>
<td>100</td>
<td>44,719 (6,791)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Asn141His Variant allele</td>
<td>129</td>
<td>43,150 (10,660)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Leu205Arg Variant allele</td>
<td>101</td>
<td>31,568 (6,485)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Thr212Met Variant allele</td>
<td>84</td>
<td>38,278 (7,244)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ser242Ile Variant allele</td>
<td>88</td>
<td>38,420 (7,310)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

N = sample size; SD = standard deviation.

doi:10.1371/journal.pgen.1004372.t003
study, the prevalence of POAG in Ghana exceeded 17%, the highest rate observed anywhere in the world [25]. While rs33912345 is not associated with POAG risk in a West African POAG case/control dataset from Ghana, the frequency of the ancestral (risk) allele is 99% in both cases and controls [26]. We hypothesize that differences in the structure of the optic nerve and the higher risk of POAG in individuals with African ancestry may, in part, arise from the fact that essentially all individuals in this population are homozygous for the rs33912345 ancestral risk allele.

Given the association of the SIX6 locus with neural retinal measurements such as VCDR, it is reasonable to hypothesize causal variants may function by inducing quantitative changes in cell populations in the retina. There is extensive evidence that SIX6 regulates early retinal progenitor cell proliferation during eye development [18,19,27]. Li et al. showed that Six6−/− mice display varying degrees of retinal hypoplasia that is due to a decrease in retinal ganglion cell proliferation arising from an early exit from the cell cycle during development, and results in a 20% decrease in the number of retinal ganglion cells by P35 [18]. This is consistent with functional studies of XOptx2, the Xenopus ortholog of SIX6 [19]. We have shown a reduction in eye size and in the volume of the optic nerve upon MO knockdown of zebrafish six6a, and we were able to rescue these phenotypes with co-injection of the human SIX6 non-risk allele, demonstrating that the zebrafish six6a gene is the likely functional ortholog to human SIX6. We identified five alleles that could not rescue the small eye and optic nerve phenotypes, and we observed a reduction in retinal nerve fiber layer thickness in POAG patients homozygous for the His141 SIX6 risk allele. Taken together with previously published findings, our results suggest that risk variants in human SIX6 increase POAG susceptibility by negatively affecting retinal ganglion cell development, likely leading to a reduction in the number of retinal ganglion cells.

Figure 3. Functional evaluation of SIX6 variants on the volume of the optic nerve. Representative whole mount images of acetylated-tubulin expression in the heads of zebrafish embryos injected with a control or six6a morpholino, rescued by co-injection with human non-risk SIX6 transcript or a transcript containing the Leu205Arg hypomorphic variant (A). Acetylated-tubulin staining is restricted primarily to axon tracts and can be used to visualize the optic nerve. Relative to the control morphants, volumetric regions of interest (ROI) along the optic nerve in six6a morphants were reduced significantly. Co-injection of human variants revealed a hypomorphic (Leu205Arg, Asn141His) or benign (Glu93Gln) role of the variants on the optic nerve (B). Sample size for all injection paradigms ranged from 7–9 and p-values are plotted for each comparison (*** p<0.001; ** p<0.01). No significant changes in the volume of other axonal tracts in the head (marked by an asterisk) were detected. Standard error of the mean is shown and white scale bars = 20 um.

doi:10.1371/journal.pgen.1004372.g003
retinal ganglion cells in adulthood. Given that retinal ganglion cells are lost during the normal aging process, we speculate that this rate of loss could be increased by the presence of additional POAG risk alleles or other risk factors such as increased intraocular pressure [28]. The development of glaucomatous optic neuropathy and associated visual field loss would thus be hastened by a reduction in the initial number of retinal ganglion cells that an individual possesses. Future work will test the possibility that SIX6 variants also alter the rate of RGC death in the adult.

In summary, we have identified multiple common and rare SIX6 sequence variants in POAG cases, and used in vivo and in vitro assays to demonstrate that these variants have functional consequences on SIX6 expression and protein function. While other risk factors may be required for the onset of POAG, our data suggest that attenuation of SIX6 protein function increases an individual’s susceptibility to developing the disease via changes to retinal development. Additional work is needed, possibly through the use of transgenic animal model studies, to fully understand the role of SIX6 in POAG.

**Figure 4. In vitro luciferase assay results showing the effect of SIX6 enhancer variants.** SIX6 enhancer alleles were tested using a dual luciferase assay and the ratio of the experimental luciferase: control luciferase was calculated (DLR ratio). All vectors were co-transfected with NeuroD and E47. In this context, the SIX6 enhancer is functioning to increase expression compared to the empty vector (pGL4.23), driven by a minimal promoter. Compared to the reference enhancer (Ref), one variant (Chr14:60974449_G) significantly increases the enhancer’s activity.

doi:10.1371/journal.pgen.1004372.g004
Materials and Methods

Ethics statement

This research was approved by the Institutional Review Board of Duke University Medical Center and adheres to the tenets of the Declaration of Helsinki.

Subjects

Study subjects were unrelated patients from the Duke Eye Center and, after a comprehensive eye examine, were classified as either POAG cases or controls. POAG cases presented with glaucomatous optic neuropathy, defined as a cup-to-disc ratio greater than 0.7 and visual field loss in at least one eye. Patients with secondary forms of glaucoma or a history of ocular trauma were excluded from the study. POAG controls had no evidence of optic neuropathy, normal intraocular pressure (less than 22 mmHg in both eyes), and normal visual fields, assessed using standard automated perimetry.

DNA sequencing

Genomic DNA was extracted from patient blood samples using the PureGene chemistry following the manufacturer’s standard protocol (Genta, Minneapolis, MN). The coding portions (2 exons) of the SIX6 gene were sequenced in 518 Caucasian POAG cases and controls (262 cases, 256 controls) using a polymerase chain-reaction (PCR) containing 1 × Qiagen PCR buffer (Tris-Cl, KCl, (NH4)2SO4, 15 mM MgCl2; pH 8.7); 200 μM each of dATP, dCTP, dGTP, and dTTP; 0.4 μM forward PCR primer; 0.4 μM reverse PCR primer; 3 μL of betaine, 10 ng genomic DNA; and 0.5 U HotStarTag DNA polymerase (Qiagen, Venlo, Limburg) to a final volume of 25 μL. Primer sequences are available in Supplemental Table S3. The PCR was performed using a touchdown protocol (incremental lowering of annealing temperature) using the following thermostable conditions: 94°C for 30 s, 65°C for 30 s, 72°C for 30 s with a 2°C decrease in the annealing temperature every two cycles until a final annealing temperature of 55°C was reached. The retinal specific SIX6 enhancer, previously described [12], was amplified a using a touchdown protocol with a final annealing temperature of 55°C. PCR products were sequencing using the BigDye chemistry on a 3730 DNA Analyzer (Applied Biosystems, Grand Island, NY).

Genotyping and imputation

The common missense single nucleotide polymorphism (SNP), rs33912345, was genotyped in the Duke DNA samples using 482 POAG cases and 433 POAG controls using a TaqMan allelic discrimination assay according to the manufacturer’s protocol (Life Technologies). For quality control purposes the following standard protocols from the manufacturer (Life Technologies, Grand Island, NY). Translation blocker (TB) morpholinos against six6a (5′- CTTGGGACATGGACAGTGTAAATGTCT -3′) and six6b (5′- AATTTGGCAACTGAAACATGGAGACTG -3′) were purchased from Gene Tools, LLC. Morpholinos (2 ng) and mRNA (12.5 pg) were mixed and a volume of 0.5 μL was microinjected into each wild-type zebrafish embryo at one- to eight-cell stage as described previously (Stuart, McMurray et al. 1988).

Microinjection of morpholino and mRNA

A vector containing human SIX6 was purchased from the CGSB Human ORFeome Collection that uses the Gateway technology system (Open Biosystems and Life Technologies, Grand Island, NY). SIX6 alleles identified by sequencing (Glu93Gln, Glu129Lys, Asn141His, Leu212Met, Ser242Ile), were created using the QuikChange II site-directed mutagenesis kit and protocols provided by the manufacturer (Agilent Technologies). SIX6 mRNA was in vitro transcribed using mMESSAGE mMACHINE SP6 Kit (Ambion, Life Technologies, Grand Island, NY). Translation blocker (TB) morpholinos against six6a and six6b were performed in patients without ocular disease, so there was limited data available for controls. Therefore, the analysis was restricted to POAG cases homozygous for rs33912345. Thirty patients had both OCT measurements and SIX6 genotype data. RNFL thickness, age at POAG diagnosis, and the age at OCT measurement were compared between individuals homozygous for the risk or non-risk allele using a Student’s t-test. Analyses were performed in SAS [29].

Morphometric analyses of zebrafish

Morphometric analyses of eye size were conducted on zebrafish embryos at 3 days post fertilization, using a Nikon SMZ 745T microscope. Zebras were anesthetized in embryo medium containing 0.2 mg/ml tricaine (Ethyl 3-aminobenzoate methanesulfonate, Sigma, E10521). Lateral view images were captured with a Nikon DS-Fi1 camera, and the size of eye was measured with Nikon NIS-Elements AR software. Analysis of the optic nerve was performed on 2 dpf embryos fixed in Dent’s fixative (80% Methanol and 20% DMSO) overnight and stained with acetylated-tubulin (Sigma; T7451). Heads were isolated from stained embryos and oriented with the ventral aspect facing a coverslip on microscope cover glass. Image acquisition was performed on a Zeiss 710 inverted confocal microscope and ~100 um optical sections were obtained and reconstructed. Volumetric measurements were calculated using Imaris software and 7.5 um × 7.5 um × 15 um ROIs along the optic nerve were analyzed between each condition. ROIs were restricted to portions of the optic nerve wherein all neurite processes coalesced to form the major aspect of the nerve.
In vitro luciferase assay

**SIX6** enhancer alleles were tested using the dual-luciferase reporter assay system (Promega, Madison, WI). An experimental construct containing a minimal promoter (pGL4.23, firefly luciferase, Promega) was used to test the functional effect of the enhancer alleles identified by sequencing (Chr14:60974363_C, Chr14:60974373_T, Chr14:60974378_T, Chr14:60974400_A, Chr14:60974449_G) in the POAG case/control dataset. The experimental constructs (pGL4.23+Enhancer) were generated using a nested PCR protocol; the XhoI and HindIII enzymes; the Quick Ligation kit (New England BioLabs, Ipswich, MA); and the QuickChange II site-directed mutagenesis kit (Agilent Technologies), following protocols provided by the manufacturers. Constructs were confirmed to be correct by sequencing. Hek293 cells were cultured according to the supplier’s suggestions (ATCC, Manassas, VA). As described by Conte et al., co-transfection with NeuroD and E47 is required for **SIX6** enhancer activation [12]. Therefore, cells were co-transfected with an experimental vector (pGL4.23+Enhancer), a control vector (pGL4.74, renilla luciferase, Promega), and vectors containing NeuroD and E47 (provided by the Center for Human Disease Modeling, Duke University) using a standard calcium phosphate transfection protocol. The experiment was performed three times in triplicate and the results were analyzed using the dual luciferase reporter (DLR) ratio (firefly luciferase sum: renilla luciferase sum) normalized by the reference **SIX6** enhancer included on every plate. The data were analyzed using an ANOVA, adjusted for batch, and linear contrasts were used to determine the effect of each vector. Statistical analyses were performed in SAS [29].

**Supporting Information**

Figure S1 Plot of the association signal from the NEIGHBOR and GLAUGEN POAG meta-analysis results observed at the SIX1/SIX6 locus calculated using chromosome 14 imputed genotype data. Generated using LocusZoom (http://genome.sph.umich.edu/wiki/LocusZoom). The color indicates the r² value with the index SNP, rs10483727.

(TIF)

Figure S2 Results from BLAST search showing homology between human SIX6 and zebrafish Six6a and Six6b. The human SIX6 protein shares 91% identity with both of the zebrafish orthologs, Six6a and Six6b. Red: conserved across all proteins; Blue: conserved across 2 proteins; Grey: not conserved.

(TIF)

Figure S3 Volumetric analysis of the optic nerve. Confocal image of a 2 dpf zebrafish head stained with antibody to acetylated tubulin to visualize axons. (A) Regions of Interest (ROIs) 7.5 um x7.5 um x15 um in size along the optic nerve were selected from reconstructed 3-dimensional images using Imaris software [X-Y plane (B-C) and X-Z plane (D-E)]. Panels C and E show the reconstructed ROI from which volumetric measurements are calculated.

(TIF)

Figure S4 In vitro luciferase assay results from the **SIX6** enhancer and co-transfection with NeuroD and E47. The **SIX6** enhancer alone was inactive compared to the empty vector (pGL4.23). Co-transfection of both NeuroD and E47 increased the enhancer’s activity. The highest activity level was reach with co-transfection of an equal amount of both, as previously described [12].

(PDF)

Figure S5 In vitro luciferase assay results showing the effect of the **SIX6** enhancer without co-transfection of NeuroD and E47. **SIX6** enhancer alleles were tested using a dual luciferase assay and the ratio of the experimental luciferase: control luciferase was calculated (DLR ratio). In the absence of NeuroD and E47, the **SIX6** enhancer is not active. However, the Chr14:60974449_G variant still shows increased enhancer activity. Coordinates are based on the Hg19 reference. P-values are provided below the mean of each vector.

(PDF)

Table S1 Coding variants identified by sequencing SIX1 and SIX6 in 518 POAG cases and controls. Coordinates are based on the Hg19 reference.

(DOCX)

Table S2 Top SNPs from the imputed Chromosome 14 POAG association analysis. Plink output from meta-analysis of the NEIGHBOR and GLAUGEN logistic regression results. OR -= odds ratio.

(DOCX)

Table S3 Primer sequences used in this study.

(DOCX)

**Acknowledgments**

**Members of NEIGHBORHOOD Consortium Investigators:**

Allingham, R. Rand (Department of Ophthalmology, Duke University School of Medicine); Brilliant, Murray (Center for Human Genetics, Marshfield Clinic); Budenz, Donald L. (Eye at Chapel Hill North, University of North Carolina School of Medicine); Chiu, Hemin R. (National Eye Institute); Cooke Bailey, Jessica (Center for Human Genetic Research, Vanderbilt University School of Medicine); Fingert, John (Department of Ophthalmology, University of Iowa Medical School); Friedman, David S. (Dana Center for Preventive Ophthalmology, Johns Hopkins Hospital); Gaasterland, Douglas (Eye Doctors of Washington (EDOW)); Gaasterland, Terry (University of California San Diego, Scripps Genome Center); Haines, Jonathan (Center for Human Genetic Research, Vanderbilt University School of Medicine); Hauer, Michael A. (Center for Human Genetics, Duke University School of Medicine); Kang, Jae H. (Johns Hopkins Division of Medical Imaging Physics); Lee, Richard K. (Bascom Palmer Eye Institute, University of Miami School of Medicine); Lichter, Paul R. (University of Michigan Kellogg Eye Center); Lai, Yutao (Molecular Genomics Core Facilities, Duke University School of Medicine); Loomis, Stephanie (Massachusetts Eye and Ear, Harvard Medical School); McCarty, Cathy Essentia (Institute of Rural Health, Duluth, MN); Moroi, Sayoko E. (University of Michigan Kellogg Eye Center); Pasquale, Louis R. (Massachusetts Eye and Ear, Harvard Medical School); Pericak-Vance, Margaret (Hussman Institute for Human Genomics at Miller School of Medicine); Realini, Anthony (Department of Ophthalmology, West Virginia University Eye Institute); Richards, Julia E. (University of Michigan Kellogg Eye Center); Schuman, Joel S. (McGovern Institute for Regenerative Medicine, University of Pittsburgh); Scott, William K. (Hussman Institute for Human Genomics at Miller School of Medicine); Singh, Kuldev (The Byers Eye Institute at Stanford, Stanford University School of Medicine); Sit, Arthur (Department of Ophthalmology, Mayo Clinic); Vollrath, Douglas (Stanford University School of Medicine); Weinreb, Robert N. (Shiley Eye Center, University of California San Diego); Wiggs, Janey L. (Massachusetts Eye and Ear, Harvard Medical School); Wollstein, Gadi (University of Pittsburgh School of Medicine); Zhang, Don (The Johns Hopkins University School of Medicine, Department of Neuroscience); Zhang, Kang (Shiley Eye Center, University of California San Diego).

A list of the NEIGHBORHOOD investigators can be found at http://glaucomagenetics.org/members (accessed March 18, 2013).
Author Contributions
Conceived and designed the experiments: MUC YPL RRA BTW AAK ECO MAH. Performed the experiments: MUC YPL SH CQ.

References


Analyzed the data: MUC YPL MEG ECO. Contributed reagents/materials/analysis tools: RRA NK JLW LRP ECO MAH. Wrote the paper: MUC MAH ECO.